{"nctId":"NCT04542330","briefTitle":"Using BCG to Protect Senior Citizens During the COVID-19 Pandemic","startDateStruct":{"date":"2020-09-15","type":"ACTUAL"},"conditions":["Covid19","Non-specific Effects of Vaccines","Heterologous Immunity","Morbidity","Immunosenescence","Vaccine Preventable Disease"],"count":1700,"armGroups":[{"label":"BCG-Denmark","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: BCG-Denmark"]},{"label":"Control","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Saline"]}],"interventions":[{"name":"BCG-Denmark","otherNames":["BCG-1331","BCG-AJ","BCG-SSI"]},{"name":"Saline","otherNames":["NaCl"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n• In order to be eligible to participate in this study, a subject must meet the following criteria: ≥65 years old.\n\nExclusion Criteria:\n\n* Known allergy to (components of) the BCG vaccine or serious adverse events in relation to prior BCG administration\n* Previous Mycobacterium tuberculosis (M. tuberculosis) infection or known active or latent infection with M. tuberculosis or other mycobacterial species\n* Previous confirmed COVID-19 infection\n* Fever (\\>38 C) within the past 24 hours or suspicion of active viral or bacterial infection\n* Vaccination with other live attenuated vaccine within the last 4 weeks\n* Severely immunocompromised subjects. This exclusion category comprises:\n* Subjects with known infection with the human immunodeficiency virus (HIV)\n* Subjects with solid organ transplantation or bone marrow transplantation\n* Subjects under chemotherapy\n* Subjects with primary immunodeficiency\n* Treatment with any anti-cytokine therapy within the last year\n* Treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months\n* Active solid or non-solid malignancy or lymphoma within the prior two years\n* Subjects who do not have access to e-Boks.","healthyVolunteers":true,"sex":"ALL","minimumAge":"65 Years","maximumAge":"110 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Acute Infection","description":"The primary outcome was a composite outcome of acute infection (recurrent events) defined as \"infection attended by a physician\", \"use of antibiotics\", \"hospitalisation due to infection\", or \"death due to infection\". All subcomponents were also analysed separately.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"424","spread":null},{"groupId":"OG001","value":"469","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"236","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"338","spread":null},{"groupId":"OG001","value":"341","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Verified SARS-CoV-2 Infection (First Event)","description":"Verified SARS-CoV-2 infection was defined as having a positive SARS-CoV-2 Polymerase Chain Reaction (PCR) test or rapid antigen test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]}]},{"type":"SECONDARY","title":"Self-reported Respiratory Symptoms (Recurrent Events)","description":"Self-reported respiratory symptoms were identified from questionnaires, where participants reported having had a respiratory illness such as common cold, influenza, pneumonia, or similar term, and/or reported one or more of the following symptoms: cough, sore throat, runny nose/nasal congestion (common cold symptoms), loss of smell or taste sense, or dyspnoea, with or without general symptoms such as fever, chills, muscle ache, headache, and fatigue (dyspnoea only if in combination with fever). This outcome also included symptoms not requiring medical attention.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"957","spread":null},{"groupId":"OG001","value":"781","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Hospitalisation (First Event)","description":"All-cause hospitalisation (first event) included all hospital admissions with overnight stay regardless of duration. Overnight stay was chosen as a condition to exclude contacts such as planned procedures and visits to outpatient clinics.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":78,"n":838},"commonTop":["Vaccination site reactions"]}}}